A systematic review and meta-analysis demonstrate miRNAs as promising biomarkers in acute lymphoblastic leukemia, suggesting new therapeutic approaches.
These findings support miRNAs as valuable prognostic biomarkers for ALL with potential for personalized therapy. The context-dependent role of these miRNAs highlights the need for confirmation through large, multicenter trials. The constructed ceRNA network provides useful insights into their regulatory mechanisms, opening new directions for therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Toutounchian et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: